布地奈德混悬液对支气管哮喘慢性持续期患者骨密度的影响  

Study on the influence of persistent inhalation of Rupumike in patients with bronchial asthma on bone density

作　　者：刘永强[1] 尹娟[2] 

机构地区：[1]保定市脑血管病医院内科 [2]河北大学附属医院体检中心,河北保定071000

出　　处：《临床和实验医学杂志》2013年第2期101-102,共2页Journal of Clinical and Experimental Medicine

摘　　要：目的通过观察支气管哮喘慢性持续期患者雾化吸入布地奈德混悬液治疗3个月骨密度的变化,评定布地奈德混悬液对机体骨质疏松的影响。方法选自门诊的支气管哮喘慢性持续期患者40例,随机分成两组,治疗组给予雾化吸入布地奈德混悬液,对照组给予安慰剂吸入,观察治疗前后骨密度变化。结果与对照组比较:治疗组临床症状、一秒钟用力呼气容积占用力肺活量百分比(FEV1/FVC)以及一秒钟用力呼气容积(FEV1)占预计值百分比明显增加,骨密度无明显变化。结论布地奈德混悬液对支气管哮喘慢性持续期患者治疗有效,且对骨密度无明显影响。Objective To observe the change in bone density in patients with chronic bronchial asthma treated by persistent inhalation of Rupumike for 3 months, and to assess the impact of Pulmicort on osteoporosis in human body. Methods Forty patients with chronic bronchial asthma in this hospital were randomly divided into two groups, patients in treatement group were treated with inhalation of Rupumike, and patients in control group were given with placebo inhalation, and bone density was observed before and after treatment. Results In comparison with pa- tients of control group, clinical symptoms and percentage of predicted value for FEV1/FVC and FEVI in patients of treatment group were signifi- cantly increased, and there was no significant change observed in bone density. Conclusion The persistent application of Pulmicort in patients with bronchial asthma has no significant effect on bone density.

关 键 词：布地奈德混悬液 支气管哮喘慢性持续期 骨密度 

分 类 号：R725.6[医药卫生—儿科]